In 2025, via executive action, President Trump directed drug manufacturers to offer consumers the most-favored-nation lowest price. Pursuant to this order, the federal government has entered into agreements with several major pharmaceutical manufacturers and unveiled a new voluntary payment model relating to Medicaid. The federal government has neither proposed nor implemented permanent most-favored-nation pricing requirements or processes, but the continued uncertainty around the pricing of drugs and devices could continue to affect our business.
